| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10044928 | HBV | ENSG00000173198.6 | protein_coding | CYSLTR1 | No | No | 10800 | Q9Y271 |
| TVIS44029725 | HTLV-1 | ENSG00000173198.6 | protein_coding | CYSLTR1 | No | No | 10800 | Q9Y271 |
| TVIS44051802 | HTLV-1 | ENSG00000173198.6 | protein_coding | CYSLTR1 | No | No | 10800 | Q9Y271 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CYSLTR1 |
|---|---|
| DrugBank ID | DB00549 |
| Drug Name | Zafirlukast |
| Target ID | BE0000705 |
| UniProt ID | Q9Y271 |
| Regulation Type | antagonist |
| PubMed IDs | 11752352; 11061985; 11979731; 11006272; 9042024; 10851239; 23859232; 12223454; 31390227; 32179525; 18031150 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Cazzola M, Boveri B, Carlucci P, Santus P, DiMarco F, Centanni S, Allegra L: Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist. Pulm Pharmacol Ther. 2000;13(6):301-5.@@Murata Y, Sugimoto O: [Zafirlukast (Accolate): a review of its pharmacological and clinical profile]. Nihon Yakurigaku Zasshi. 2002 Apr;119(4):247-58.@@Wang S, Gustafson E, Pang L, Qiao X, Behan J, Maguire M, Bayne M, Laz T: A novel hepatointestinal leukotriene B4 receptor. Cloning and functional characterization. J Biol Chem. 2000 Dec 29;275(52):40686-94.@@O'Byrne PM: Leukotrienes in the pathogenesis of asthma. Chest. 1997 Feb;111(2 Suppl):27S-34S.@@Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, Cheng R, Williams DL Jr, Zeng Z, Liu Q, Ma L, Clements MK, Coulombe N, Liu Y, Austin CP, George SR, O'Neill GP, Metters KM, Lynch KR, Evans JF: Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000 Sep 29;275(39):30531-6.@@Singh RK, Tandon R, Dastidar SG, Ray A: A review on leukotrienes and their receptors with reference to asthma. J Asthma. 2013 Nov;50(9):922-31. doi: 10.3109/02770903.2013.823447. Epub 2013 Aug 16.@@McMahon B, Mitchell D, Shattock R, Martin F, Brady HR, Godson C: Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J. 2002 Nov;16(13):1817-9. doi: 10.1096/fj.02-0416fje. Epub 2002 Sep 5.@@Figueroa EE, Kramer M, Strange K, Denton JS: CysLT1 receptor antagonists pranlukast and zafirlukast inhibit LRRC8-mediated volume regulated anion channels independently of the receptor. Am J Physiol Cell Physiol. 2019 Oct 1;317(4):C857-C866. doi: 10.1152/ajpcell.00281.2019. Epub 2019 Aug 7.@@Ruiz I, Nevers Q, Hernandez E, Ahnou N, Brillet R, Softic L, Donati F, Berry F, Hamadat S, Fourati S, Pawlotsky JM, Ahmed-Belkacem A: MK-571, a Cysteinyl Leukotriene Receptor 1 Antagonist, Inhibits Hepatitis C Virus Replication. Antimicrob Agents Chemother. 2020 May 21;64(6). pii: AAC.02078-19. doi: 10.1128/AAC.02078-19. Print 2020 May 21.@@Reques FG, Rodriguez JL: Tolerability of leukotriene modifiers in asthma: a review of clinical experience. BioDrugs. 1999 Jun;11(6):385-94. doi: 10.2165/00063030-199911060-00003. |
| Groups | Approved; Investigational |
| Direct Classification | Benzenesulfonamides |
| SMILES | COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C |
| Pathways | |
| PharmGKB | PA451949 |
| ChEMBL | CHEMBL603 |
